Experimental Lilly combination drug tops Zepbound in weight-loss trial
Eli Lilly's experimental drug EloraTZP outperformed tirzepatide in weight loss for patients with obesity and type 2 diabetes. The therapy combines tirzepatide with eloralintide, an experimental amylin drug. High-dose EloraTZP users lost an average of 23.3% of their body weight, while those using tirzepatide alone lost 14.8%. Despite these results, discontinuation rates for the combination therapy were significantly higher than for the standalone treatment. Lilly intends to start Phase 3 testing for the drug in the fourth quarter of 2026.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β EloraTZP combines tirzepatide with the experimental amylin drug eloralintide.
- β Patients on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
- β Patients using tirzepatide alone lost an average of 14.8% of their body weight.
- β Eli Lilly plans to begin Phase 3 testing for the therapy in the fourth quarter of 2026.
What changed
Recent reports confirm the experimental combination of eloralintide and tirzepatide is currently under testing for enhanced weight loss.
Live updates
-
Lilly combination drug EloraTZP outperforms tirzepatide in weight-loss trial
Eli Lilly's experimental drug EloraTZP outperformed tirzepatide in weight loss for patients with obesity and type 2 diabetes. The therapy combines tirzepatide with eloralintide, an experimental amylin drug. High-dose EloraTZP users lost an average of 23.3% of their body weight, while those using tirzepatide alone lost 14.8%. Despite these results, discontinuation rates for the combination therapy were significantly higher than for the standalone treatment. Lilly intends to start Phase 3 testing for the drug in the fourth quarter of 2026.
Why it matters
The trial tests if a three-hormone approach provides superior efficacy over current GLP-1 treatments. Success in Phase 3 would position EloraTZP as a more potent alternative to Zepbound.
What is confirmed
- EloraTZP combines tirzepatide with the experimental amylin drug eloralintide.
- Patients on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
- Patients using tirzepatide alone lost an average of 14.8% of their body weight.
- Eli Lilly plans to begin Phase 3 testing for the therapy in the fourth quarter of 2026.
Still unconfirmed
- Discontinuation rates for EloraTZP were far higher than for standalone tirzepatide treatment.
What to watch next
- Commencement of Phase 3 testing in Q4 2026
- Disclosure of specific discontinuation rate percentages
confidence 90%Sources used for this update (2)
- www.tradingkey.com β Todayβs Market Recap: OpenAI Revenue Concerns; Nasdaq Falls 1.25%, AAOI Drops 13.58%, Brent Gains 4.07%
- madamenoire.com β Eli Lilly's New Weight-Loss Drug Shows Eye-Popping Results
-
Eli Lilly experimental drug combo EloraTZP outperforms Zepbound in weight-loss trial
Eli Lilly's experimental combination drug EloraTZP achieved greater weight loss than tirzepatide alone in patients with type 2 diabetes and obesity. Patients receiving the highest dose of EloraTZP lost an average of 23.3% of their body weight, compared to 14.8% for those on tirzepatide alone. The regimen combines tirzepatide with eloralintide, an experimental amylin drug. While the combination shows superior efficacy, some reports indicate discontinuation rates were far higher than for the standalone treatment. Lilly plans to begin Phase 3 testing for the therapy in the fourth quarter of 2026.
Why it matters
Lilly and Novo Nordisk are both developing amylin-targeting drugs to complement or replace GLP-1 treatments. This move comes as Zepbound has already demonstrated superiority over Novo Nordisk's Wegovy in head-to-head trials. The competition for the obesity market is estimated to be a 100 billion dollar opportunity.
What is confirmed
- Patients on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
- Patients receiving only tirzepatide lost 14.8% of their body weight.
- EloraTZP combines tirzepatide with the experimental amylin drug eloralintide.
- Eli Lilly intends to start Phase 3 testing for the regimen in the fourth quarter of 2026.
- Zepbound outperformed Novo Nordisk's Wegovy in the first head-to-head weight-loss trial.
- Eli Lilly reported annual revenue of $65.18B with a net profit of $20.64B.
Still unconfirmed
- Discontinuation rates for the EloraTZP combination were far higher than for Zepbound alone.
- Eli Lilly's market capitalization is roughly $1.1 trillion.
What to watch next
- Phase 3 trial initiation in Q4 2026
- FDA decisions on amylin-targeting combinations
- Detailed data on EloraTZP discontinuation rates
confidence 90%Sources used for this update (20)
- www.glp1authority.com β GLP-1 News & Updates β Daily Summaries | GLP1Authority
- pharmaphorum.com β Zepbound tops Wegovy in first head-to-head weight-loss trial
- stocktwits.com β Stocktwits - Stock Market Live Quotes, Social Community...
- rocketnews.com β Why Lilly and Novo are betting on amylin to power a new wave ...
- www.fool.com β Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be ...
- health.yahoo.com β Eli Lillyβs New Drug Combo Just Set A Record For Weight Loss ...
- stocktwits.com β Skydance CEO David Ellison Outlines 4 Goals For Merger Success, Company Targets $2B In First-Year Synergi....
- www.tradingkey.com β Eli Lilly and Co Stock (LLY) Moved Down by 3.09% on Oct 8: Facts Behind the Movement
- www.advisory.com β Around the nation: Eli Lilly's new obesity drug combo boosts ...
- pharmaphorum.com β More data backs Zepbound over Wegovy for weight loss
- blavity.com β Eli Lilly's New Drug Combo Just Set A Record For Weight Loss ...
- www.tradingkey.com β Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement
-
Eli Lilly combination drug EloraTZP outperforms tirzepatide in Phase 2 trial
Eli Lilly's experimental drug EloraTZP produced greater weight loss in patients with type 2 diabetes and obesity than tirzepatide alone. Patients on the highest dose of the combination therapy lost an average of 23.3% of their body weight, while those receiving only tirzepatide lost 14.8%. EloraTZP mixes tirzepatide with eloralintide, an experimental amylin drug. The company intends to start Phase 3 testing for the regimen in the fourth quarter of 2026.
Why it matters
The results target a patient population struggling with both obesity and diabetes. This combination therapy builds upon the existing success of Zepbound and Mounjaro. Lilly aims to expand a portfolio that already generates billions in revenue.
What is confirmed
- EloraTZP outperformed tirzepatide in a Phase 2 trial involving patients with type 2 diabetes and obesity.
- Patients on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
- Patients receiving tirzepatide alone lost an average of 14.8% of their body weight.
- EloraTZP combines tirzepatide with the experimental amylin drug eloralintide.
- Eli Lilly plans to begin Phase 3 trials for the combination by the end of 2026.
What to watch next
- Initiation of Phase 3 clinical trials in Q4 2026
- Publication of detailed safety data for the eloralintide combination
confidence 100%Sources used for this update (3)
- www.zerohedge.com β Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics | ZeroHedge
- primexbt.com β Eli Lilly's Weight Loss Combo EloraTZP Beats Tirzepatide in Phase 2 Trial
- dictionary.cambridge.org β EXPERIMENTAL | English meaning - Cambridge Dictionary
-
Eli Lilly combo drug EloraTZP outperforms Zepbound in weight-loss trial
Eli Lilly reported that its experimental combination drug EloraTZP outperformed Zepbound in a head-to-head mid-stage trial. Patients with diabetes receiving the highest tested dose of EloraTZP lost an average of 23.3% of their body weight, compared to 14.8% for those receiving tirzepatide alone. EloraTZP combines tirzepatide with the experimental amylin drug eloralintide. Following these results, the Indianapolis-based pharmaceutical company plans to initiate Phase 3 trials for the combination regimen by the end of 2026.
Why it matters
Lilly is competing with Novo Nordisk to develop more effective obesity therapies by using multiple biological levers. This approach follows the development of retatrutide, a triple-hormone drug simulating GLP-1, GIP, and glucagon. Amylin drugs represent a new category of treatment for obesity and diabetes.
What is confirmed
- EloraTZP combines tirzepatide and the experimental drug eloralintide.
- Patients with diabetes on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
- Tirzepatide alone produced 14.8% weight loss in the same Phase 2 diabetes trial.
- Eli Lilly plans to start Phase 3 trials for the combination regimen at the end of the year.
- Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
Still unconfirmed
- Lilly stocks dropped as EloraTZP results tested tolerability.
- Retatrutide delivers an average weight loss of 50 pounds.
What to watch next
- Launch of Phase 3 trials for EloraTZP at the end of 2026
- Further data on the tolerability of the eloralintide and tirzepatide combination
confidence 100%Sources used for this update (13)
- The Guardian β βGodzillaβ of weight-loss drugs could provide other important health benefits
- CNBC β Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- arstechnica.com β Most powerful obesity drug yet: People lost up to 25% of ...
- Reuters β Experimental Lilly combination drug tops Zepbound in weight-loss trial
- USA Today β Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
- Fierce Biotech β Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
- www.biopharmadive.com β 3 takeaways from a European obesity scientific meeting | BioPharma Dive
- www.medicaldaily.com β Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 D....
- finance.yahoo.com β Experimental Lilly combination drug tops Zepbound in weight-loss trial
- www.cnbc.com β Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial
- www.gurufocus.com β Lilly Stocks Drop as EloraTZP Beats Zepbound but Tests Tolerability
- www.cnbc.com β Lilly, Novo bet on amylin obesity drugs after GLP-1s
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community